Core Insights - The 22nd World Traditional Chinese Medicine Conference was held in Sydney, Australia, focusing on the theme of "Cultural Dissemination and Technological Innovation of Traditional Chinese Medicine (TCM) from a Global Perspective" [1][3] Group 1: Conference Overview - The conference was organized by the World Federation of Chinese Medicine Societies and supported by various Australian organizations, including the Australian Conference Bureau and the Australian Tourism Bureau [3] - Key participants included TCM experts, government officials, and business representatives from around the world, engaging in discussions on the international development of TCM [1][3] Group 2: Company Initiatives - Guangzhou Pharmaceutical Group, a major partner of the conference, showcased its latest achievements in TCM internationalization, technological innovation, and cultural dissemination [3] - The company’s chairman, Li Xiaojun, emphasized the importance of modernizing TCM through digital transformation and establishing a comprehensive international presence [3][6] Group 3: Strategic Collaborations - During the conference, Guangzhou Pharmaceutical Group signed multiple strategic cooperation agreements with various international entities, focusing on cultural promotion, research collaboration, and market expansion [8] - Notably, the Wanglaoji Health Company plans to launch the WALOVI international can in Australia, enhancing its overseas market presence [8] Group 4: Expert Contributions - The conference featured expert lectures, including a report on the regulation of TCM by Diane Wilkinson from the Australian government, providing policy guidance for TCM internationalization [6] - Other presentations included discussions on continuous innovation in TCM products, highlighting the collaborative efforts in research and development [6]

Core Insights - The recent strategic moves by Gu Sheng Tang, a leading Chinese traditional medicine chain, include a partnership with 1doc in Singapore, the launch of "National Medicine AI Avatar," and collaboration with financial institution AGP, marking a significant shift from product export to service system export in traditional Chinese medicine (TCM) internationalization [2][3][4]. Group 1: Strategic Partnerships - Gu Sheng Tang's collaboration with 1doc involves a shareholding structure where Gu Sheng Tang holds 70% and is responsible for operations, allowing for deep integration of TCM services within the existing Western medical framework [3][4]. - This partnership enables patients to receive integrated TCM and Western medical treatment within the same healthcare ecosystem, enhancing the overall healthcare management experience [4]. Group 2: Policy Alignment and Market Opportunities - The partnership aligns with Singapore's government policy promoting the integration of TCM and Western medicine, particularly the "Traditional Chinese Medicine Integration Sandbox" plan set to launch in 2025 [4][5]. - Singapore's open market and innovative policies provide a high-standard international testing ground for Gu Sheng Tang's TCM practices, which could be replicated in Southeast Asia and globally [5][9]. Group 3: Technological Advancements - The launch of the "National Medicine AI Avatar" aims to standardize and replicate TCM practices, providing an intelligent learning platform for overseas TCM practitioners [7][8]. - This AI system is designed to alleviate the shortage of qualified TCM practitioners abroad and assist in developing precise treatment plans, thereby establishing high-quality TCM service standards in international markets [7][8]. Group 4: Capital Support - Gu Sheng Tang's strategic partnership with AGP will provide direct investment to support its internationalization strategy and AI technology development, enhancing its global healthcare footprint [8]. - The investment from AGP, a spin-off from Singapore's state strategic fund, not only offers financial backing but also access to a network of healthcare resources and insights into international market regulations [8]. Group 5: Industry Implications - The developments signify a paradigm shift in TCM internationalization from isolated cultural exports to a systematic and integrated approach within local healthcare ecosystems [9]. - Singapore serves as an ideal testing ground for this new model, which, if successful, could lead to rapid replication in other international markets [9].

Core Insights - The recent strategic moves by Guoshengtang, including partnerships with 1doc and AGP, signify a pivotal shift in the internationalization of traditional Chinese medicine (TCM) from merely exporting products to establishing a comprehensive service system [1][4][5] Group 1: Strategic Partnerships - Guoshengtang has completed a significant equity partnership with Singapore's 1doc, where Guoshengtang holds a 70% stake, ensuring deep integration of TCM services within the existing Western medical framework [5][6] - The collaboration with 1doc allows for a comprehensive health management approach, offering patients a combination of TCM and Western medicine within the same healthcare ecosystem [5][6] - The partnership aligns with Singapore's government initiatives promoting the integration of TCM into mainstream healthcare, particularly through the upcoming "Traditional Chinese Medicine Integration Sandbox" plan [5][6] Group 2: Technological Innovations - The launch of the "National Medicine AI Avatar" aims to standardize and replicate TCM practices, providing a platform for overseas practitioners to enhance their clinical skills [6][9] - This AI system is designed to assist local TCM practitioners in formulating precise treatment plans, thereby establishing high-quality TCM service standards in international markets [9][10] - The integration of AI technology in TCM practices has garnered recognition from Singapore's government, indicating strong support for innovative approaches in traditional medicine [9][10] Group 3: Capital Support - Guoshengtang's strategic partnership with AGP will provide direct investment to support its internationalization strategy and AI technology development [7][10] - AGP's investment not only offers financial backing but also access to a network of healthcare resources and insights into international market regulations [10] - The capital infusion reflects confidence in Guoshengtang's ability to address core challenges in TCM's international expansion through a systematic approach combining AI and operational integration [10]

Core Viewpoint - The strategic partnership between Guoshengtang and Singapore's 1doc aims to integrate Traditional Chinese Medicine (TCM) into the mainstream medical system in Singapore, marking a significant milestone for the internationalization of TCM [1][4]. Group 1: Partnership Details - Guoshengtang and 1doc will systematically introduce TCM services in Western medical family clinics in Singapore, providing a collaborative healthcare experience that covers clinical diagnosis, daily health care, and community health [1][3]. - The partnership will involve a shareholding structure where Guoshengtang holds 70% and 1doc holds 30%, ensuring deep integration and professional operation of TCM services within Western medical settings [3][4]. - Patients will benefit from a comprehensive healthcare management approach that includes prevention, diagnosis, and rehabilitation, facilitated by TCM practitioners who can prescribe necessary tests to enhance diagnostic accuracy [3][4]. Group 2: Policy and Market Context - The Singapore government has been actively promoting the integration of TCM and Western medicine, exemplified by the "TCM Integration Sandbox Program" set to launch in 2025, which will test and evaluate TCM treatment plans in public healthcare institutions [4][5]. - 1doc, a subsidiary of IHG, operates a network of clinics in Singapore and has served over 79,000 patients, providing a strong local medical network and digital technology support for the implementation of TCM [4][5]. - Guoshengtang, as China's first publicly listed TCM chain, has established over 80 medical institutions in China and Singapore, serving more than 20 million customers and accumulating extensive clinical data to support the efficacy and safety of TCM [4][5]. Group 3: Future Prospects - The collaboration aims to create a "New TCM" service model in Singapore, exploring more partnership models to build a new ecosystem of collaborative diagnosis and treatment [5]. - The innovative policies and market openness in Singapore provide a high-standard international testing ground for Guoshengtang, with potential for replicating successful models in Southeast Asia and globally [5].

Core Viewpoint - The strategic partnership between Guoshengtang and Singapore's 1doc marks a significant milestone in integrating Traditional Chinese Medicine (TCM) into Singapore's mainstream healthcare system, promoting the internationalization of TCM [1][4]. Group 1: Partnership Details - Guoshengtang and 1doc will systematically introduce TCM services in Western medical family clinics in Singapore, providing a collaborative healthcare experience that covers clinical diagnosis, daily health care, and community health [1][3]. - The partnership structure involves Guoshengtang holding 70% and 1doc holding 30% of the TCM operations, ensuring deep integration and professional management of TCM services within Western medical settings [3][4]. - Patients will benefit from a comprehensive health management approach that includes prevention, diagnosis, and rehabilitation, facilitated by TCM practitioners who can prescribe necessary tests to enhance diagnostic accuracy [3][4]. Group 2: Policy and Market Context - The Singapore government has been actively promoting the integration of TCM and Western medicine, exemplified by the "TCM Integration Sandbox Program" set to launch in 2025, which will test and evaluate TCM treatment plans in public healthcare institutions [4][5]. - 1doc, a subsidiary of IHG, operates a robust network of clinics in Singapore, leveraging advanced technologies to support personalized and preventive healthcare, which will aid in the implementation of TCM services [4][5]. - Guoshengtang, as China's first publicly listed TCM chain, has established over 80 medical institutions in China and Singapore, serving more than 20 million patients, and has accumulated extensive clinical data to support the efficacy and safety of TCM [4][5]. Group 3: Future Prospects - The collaboration aims to create a "New TCM" service model in Singapore, exploring more partnership models to build a new ecosystem of collaborative diagnosis and treatment [5]. - Singapore's innovative policies and market openness provide a high-standard international testing ground for Guoshengtang, with potential for replicating successful models in Southeast Asia and globally [5].

Core Viewpoint - The strategic partnership between Gu Shengtang and 1doc marks a significant milestone for the integration of Traditional Chinese Medicine (TCM) into Singapore's mainstream healthcare system, promoting the internationalization of TCM [1][4]. Group 1: Partnership Details - Gu Shengtang and 1doc will systematically introduce TCM services in Western medical family clinics in Singapore, providing a collaborative healthcare experience that covers clinical diagnosis, daily health care, and community health [1][3]. - The partnership structure involves Gu Shengtang holding 70% of the shares and fully managing operations, while 1doc holds 30%, ensuring deep integration and professional operation of TCM services within Western medical settings [3][4]. - Patients will benefit from a comprehensive health management approach that includes prevention, diagnosis, and rehabilitation, facilitated by TCM practitioners who can prescribe necessary tests to enhance diagnostic accuracy [3][4]. Group 2: Supportive Environment - The Singaporean government actively promotes the integration of TCM and Western medicine, exemplified by the "TCM Integration Sandbox Program" set to launch in 2025, which will test and evaluate TCM treatment plans in public healthcare institutions [4]. - 1doc, a subsidiary of IHG, operates a robust network of clinics in Singapore, leveraging advanced digital technologies to support personalized and preventive healthcare, which will bolster the implementation of TCM [4][5]. - Gu Shengtang, as the first publicly listed TCM chain in China, has established over 80 medical institutions and served more than 20 million clients, providing a strong evidence base for the efficacy and safety of TCM [4][5]. Group 3: Future Prospects - The collaboration aims to create a "New TCM" service model in Singapore, representing Gu Shengtang's exploration of digital integration into international healthcare systems [5]. - Future plans include exploring more partnership models to build a collaborative healthcare ecosystem, promoting standardized and scalable development of TCM in international markets [5]. - Singapore's innovative policies and market openness provide a high-standard testing ground for Gu Shengtang, with potential for replicating successful models across Southeast Asia and globally [5].

Core Viewpoint - The "10th Diplomatic Envoys Traditional Chinese Medicine Health Day - Sanlitun International Week" held in Beijing emphasizes the role of traditional Chinese medicine (TCM) as a bridge connecting traditional wisdom with modern needs, promoting global health and cultural exchange [1][3]. Group 1: Development and Innovation in TCM - Chaoyang District is the first national demonstration pilot for the inheritance and innovation of TCM, housing nearly 20% of the city's TCM medical institutions and striving to create a "Digital TCM Valley" [1][3]. - The district has signed family doctor service agreements with 58 embassies, enhancing the international influence of TCM through initiatives like "Talking TCM by the Liangma River" [1][3]. Group 2: Integration of TCM and Western Medicine - Chaoyang District has established community health service centers that fully integrate TCM and Western medicine, with 100% of centers offering TCM services and a coverage rate of 67.6% for TCM clinics [3]. - A pilot program has been initiated in 10 community health service centers to develop flagship centers for TCM and Western medicine collaboration, significantly increasing the number of TCM consultation rooms and enhancing the capabilities of TCM specialists [3]. Group 3: Digital Transformation in TCM - A digital innovation system for TCM has been developed, including a digital training platform, a living inheritance database, and an intelligent training system, with over 2,000 video courses available for training [5]. - The "Famous Old TCM Doctors Experience Inheritance Project" has trained over a thousand students, providing a solid technical foundation for digital TCM physician training [5]. Group 4: International Participation and Recognition - The event gathered over 100 foreign guests from 51 countries and 2 international organizations, showcasing the achievements in the internationalization of TCM [5].

Core Insights - The event "European Pioneer Selection Conference" held in Paris showcased various brands, including Zhangzhou Pien Tze Huang Pharmaceutical Co., which highlighted its products combining traditional wisdom and modern technology [1] Group 1: Event Overview - The selection conference attracted hundreds of brands and buyers from China and Europe, marking a key activity of the 2025 China-France Brand Week [1] - Pien Tze Huang's booth featured a blend of French romantic style and technological design, displaying both traditional medicines and beauty products [3] Group 2: Product Offerings - Pien Tze Huang's product range included pharmaceuticals, cosmetics, and health foods, addressing European consumers' needs for convenient medication and natural ingredients [4] - The company introduced a "Night Recovery Set" targeting the "sub-health" issues of European professionals, which includes popular products like lozenges and goji berry essence [4] Group 3: Marketing Strategy - The company employed a dual strategy of academic research and experiential marketing to bridge cultural gaps, using scientific conclusions and experimental data to educate consumers about the benefits of traditional Chinese medicine [5] - The success at the selection conference demonstrated that traditional Chinese medicine can appeal to global consumers, positioning Pien Tze Huang as a bridge between Eastern and Western health philosophies [5]

Core Insights - The "2025 Hong Kong International Traditional Chinese Medicine Conference" was held in Hong Kong, focusing on promoting high-quality TCM globally, attracting nearly 500 experts and representatives from various regions [1] - The conference received strong support from the National Administration of Traditional Chinese Medicine and the Hong Kong government, aiming to build a high-end platform for collaboration and cultural exchange in the TCM industry [2] - Pianzaihuang Company showcased its core products at the conference, highlighting its efforts in modernizing and internationalizing traditional Chinese medicine [1][5] Group 1: Industry Development - The conference emphasized the importance of collaboration in the TCM industry, launching the "High-Quality Development of the Traditional Chinese Medicine Industry Chain" initiative, with Pianzaihuang Company as a key signatory [2] - Pianzaihuang is recognized as a leading brand in the TCM sector, consistently ranking among the top exporters of Chinese patent medicines [3] Group 2: Product Showcase - Pianzaihuang's exhibition featured a range of traditional Chinese medicines and health products, attracting significant attention from industry experts and media, enhancing its brand recognition in the Greater Bay Area and international markets [4] - The company received positive feedback for its commitment to preserving traditional techniques while promoting technological innovation in its products [4] Group 3: Strategic Goals - The participation in the conference is part of Pianzaihuang's strategy to accelerate the internationalization of TCM and expand its global influence [5] - The company aims to leverage Hong Kong's unique position as a cultural bridge to enhance its international partnerships and explore overseas opportunities [5]

紫荆文化集团董事长许正中致辞表示，本次大会涵盖交流合作、学术研讨、文化传播三大核心领 域，将积极拓展产学研合作交流，深化前沿学术探讨与智慧共享，创新中医药文化国际传播，助力中医 药高质量发展。 新华社香港9月25日电（曹霁阳、郭辛）由紫荆文化集团主办、紫荆杂志社承办的2025香港国际中 医药大会25日在香港会议展览中心开幕。近500位专家学者、行业领袖及企业代表参会，超过130家机构 参展。 本次大会为期四天，以"推动中医药高质量走向世界"为主题，通过稀有中药材展览、中医药文化体 验、中医药产品展销、名医讲座等形式，展现中医药的实用价值与发展前景，吸引政、产、学、研各界 代表参与，共商中医药国际化发展的新路径与新机遇。 全国政协副主席梁振英致辞表示，香港的中医药事业正在积极主动融入国家的中医药发展大局，同 时起步走向国际。在中医药走向国际与各国传统医药交流合作这个重大课题上，我们要秉持文明互鉴的 理念，坚持互补互利精神，加强沟通，促进相互学习、相互提高，努力共同构建人类卫生健康共同体。 香港特区政府政务司司长陈国基在致辞中说，香港发展中医药具有独特的双重优势，既有祖国深厚 的中医药文化资源和底蕴，也有与国际接 ...